Matthew Coghlan is a highly motivated and adaptable scientific professional with 20 years of experience in biopharmaceutical Research and Development within the Cardiovascular and Metabolic Disease Therapy Area. They have held leadership roles at organizations such as MedImmune, Eli Lilly and Company, Novo Nordisk, and AstraZeneca, where they specialized in project management and strategic development. Currently, Matthew is the Vice President of External Innovation & Data Science for Diabetes Obesity & Cardiometabolic TA at Eli Lilly and Company. Matthew holds a PhD from the University of Cambridge and has completed post-doctoral research at Harvard Medical School.
This person is not in any teams
This person is not in any offices